Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PEMH hospital rawalpindi | Other Identifier | PEMH rawalpindi |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
study was conducted on middle aged male and female, including families and health care professional also.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 (Triple combination group) | Experimental | participants in this arm will receive topical westerhoff formula cream which is combination of 4.7% of N-acetylcysteine, 2% hydroquinone and 0.1% Triamcinolone acetate twice daily for 8 weeks for the treatment of facial melasma |
|
| Arm 2 (4 % Hydroquinone) | Active Comparator | participant in this group will receive 4% hydroquinone twice daily for 8 weeks for the facial melasma. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Triple combination cream | Drug | 4.7% N-acetylcysteine, 2% Hydroquinone and 0.1 % triamcinolone acetate twice daily for 8 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| proportion of participants achieving 60% reduction in the melasma area severity index (MASI-60) | the primary outcome is the proportion of the participants achieving 60% reduction in MASI score from baseline after 8 weeks of treatment. MASI is the scoring system used to assess the melasma on the basis of severity darkness and the homogeneityenicity | 8 weeks |
| proportion of participants achieving >60% reduction in Melasma Area and severity index (MASI-60) | The primary outcome is the proportion of the participants achieving 60% reduction in MASI Score rom the baseline after treatment. MASI is the scoring system used to assess the severity of melasma based on the area, darkness nd the homogeneity | baseline to 8 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Female gender of reproductive age
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| QAMMAR khan DR, MBBS. FCPS(Dermatalogy) | Pak Emirates Military Hospital | Study Director |
| Moizza tHAIR Dr, MBBS.FCPS(Dermatology) | Pak Emirates Military Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dermatology Department of Tertiary Care Hospital | Rawalpindi | Punjab Province | 46000 | Pakistan |
De-identify patient data, MASI and treatment allocation
DATA WILL BE AVAILABLE AFTER PUBLICATION FOR A PEROID OF ONE YEAR
ACCESS TO THE CLINICAL STUDY REPORT WILL BE PROVIDED TO QUALIFIED RESEARCHER UPON REASONABLE REQUEST TO A PRICIPLE INVESTIGATO
Not provided
| ID | Term |
|---|---|
| D008548 | Melanosis |
| ID | Term |
|---|---|
| D017495 | Hyperpigmentation |
| D010859 | Pigmentation Disorders |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C031927 | hydroquinone |
Not provided
Not provided
Not provided
participants will be assigned to two parallel groups receiving either triple combination therapy or 4% hydroquinone cream and outcome will be compared between groups
Not provided
Not provided
Not provided
| Hydroquinone 4% Cream | Drug | twice daily for 8 weeks |
|